The Global Biologics Market is valued at US$ 626.2 billion in 2025 and is projected to reach US$ 1,464.9 billion by 2034, expanding at a CAGR of 9.9% from 2025 to 2034. The market is experiencing continued growth as pharmaceutical and biotechnology companies invest in innovative biologic therapies for complex and chronic diseases.

Biologics Market Overview

Biologics are medicines developed using living organisms or biological processes. They include monoclonal antibodies, vaccines, recombinant proteins, cell and gene therapies, blood products, and biosimilars.

Unlike conventional drugs developed primarily through chemical synthesis, biologics rely on sophisticated biological technologies and are increasingly used to address complex conditions such as cancer, autoimmune diseases, rare diseases, diabetes, and infectious diseases.

The market encompasses the research, development, manufacturing, and distribution of biologic therapies across pharmaceutical companies, biotechnology firms, hospitals, clinics, and research institutions.

A recent development highlights the pace of innovation in this industry. In June 2026, Vertex Pharmaceuticals confirmed FDA acceptance of the BLA filing for povetacicept, an investigational biologic treatment for IgA nephropathy, with a target action date of November 2026. The development demonstrates continued investment in next-generation biologic therapies.

Key Factors Driving the Biologics Market

The market is supported by several important factors:

• Increasing investment in biopharmaceutical research
• Growing development of monoclonal antibodies
• Expansion of cell and gene therapies
• Rising demand for targeted treatments
• Increasing prevalence of complex and chronic diseases
• Growing biologics manufacturing capacity
• Continued development of biosimilars

These factors are encouraging pharmaceutical and biotechnology companies to expand their research pipelines and manufacturing capabilities.

North America Biologics Market

North America represents a prominent region in the biologics market, supported by biotechnology infrastructure, research investment, regulatory capabilities, and advanced manufacturing facilities.

According to the information provided, the FDA's Center for Drug Evaluation and Research approved 50 novel drugs in 2025, reflecting continued pharmaceutical innovation. The NIH also provided more than US$ 48 billion in fiscal-year 2025 funding for biomedical research.

In April 2026, Eli Lilly and Company expanded biologics manufacturing capabilities at a new facility in Lebanon, Indiana, supported by an investment of approximately US$ 5.3 billion. The facility is intended to manufacture injectable biologic medicines and expand production capacity.

Biologics Market Segmentation

The market is segmented by:

• Product Type
• Source
• Manufacturing Type
• Route of Administration
• End User
• Distribution Channel

Get the Complete Biologics Market Report

The Biologics Market Report by RNP Market Research provides detailed insights into market size, growth trends, segmentation, regional analysis, industry developments, and emerging opportunities.

Looking for detailed market data or customized research? Contact RNP Market Research to discuss your requirements.

Source: RNP Market Research